Skip to main content

Incorrect Packaging Leads To Recall of Birth Control Pill

Incorrect Packaging Leads To Recall of Birth Control Pill

Incorrect Packaging Leads To Recall of Birth Control Pill

Introduction

On March 4, the FDA advised a nationwide birth control pill recall by Apotex Corp. impacting four lots of Drospirenone and Ethinyl Estradiol tablets, which may have placebo pills in the wrong area or missing tablets.

The recalled birth control pill packs might contain defective blisters with wrong tablet arrangements or empty blister pocket. This might lead the women to take tablets in the wrong order, lowering the effectiveness in preventing pregnancy. The FDA officials warned women need not discontinue taking birth control pills; however, they should follow a non-hormonal method of birth control too, while on the pills. The recall affected packs of tablets with lot numbers, 7DY008A,7DY009A, 7DY010A, and 7DY011A with NDC number 60505-4183-3 on the outer carton. The expiration date is listed as 8/2020.

The pills were manufactured by Oman Pharmaceutical Products, Co. LLC. and distributed by Apotex Corp. According to Apotex, no case of unintended pregnancy was reported.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

First Federal Bellwether Trial Set in Strattice Mesh Case

Categories: Hernia Mesh

Lawyers involved in federal Strattice hernia mesh litigation are scheduled to meet with the presiding judge in the U.S. District Court for the District of New Jersey to…

Tepezza Hearing Loss Trial Set for June 2026

Categories: Tepezza

The U.S. District Judge overseeing all federal Tepezza lawsuits has postponed the start of the first bellwether trial by 60 days.

This decision comes as attorneys…

FDA Moves to Restrict Dangerous 7-OH Opioid Products

Categories: Opioids

In a significant move to combat the ongoing opioid crisis, the U.S. Food and Drug Administration (FDA) has recommended a scheduling action under the Controlled Substances Act (CSA) to regulate certain products containing 7-hydroxymitragynine (7-…

✍️ FREE — 2,800 Pages Legal Process Outsourcing Trial!                 
No Contract. No Risk — Full Mass Tort + LPO Access, Free!

Only 10 Firms Accepted—Offer Ends August 31!